Firebrick Pharma Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net loss was AUD 0.898418 million compared to AUD 3.13 million a year ago. Basic loss per share from continuing operations was AUD 0.0051 compared to AUD 0.0185 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.069 AUD | +16.95% | +15.00% | +38.00% |
01:10am | Firebrick Pharma Launches Nasodine Nasal Spray in Singapore | MT |
05-23 | Firebrick Pharma Obtains Nasodine Composition Patent in South Africa | MT |
1st Jan change | Capi. | |
---|---|---|
+38.00% | 7.72M | |
+50.08% | 781B | |
-7.12% | 350B | |
+18.41% | 330B | |
+7.43% | 293B | |
+16.91% | 248B | |
+0.53% | 221B | |
+11.06% | 217B | |
+3.51% | 162B | |
-3.84% | 157B |
- Stock Market
- Equities
- FRE Stock
- News Firebrick Pharma Limited
- Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2023